Chief Legal Officer · 4D Molecular Therapeutics, Inc. · 4D Molecular Therapeutics, Inc. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
9,810
Price
—
Executed
Jun 23, 2026
Disclosed
Jun 25, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 23 executedJun 25, 2026 disclosed
FDMT · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 18.2% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
4D Molecular Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
FDMT
Shares
9,810
Price per share
$0
Execution date (reported)
Jun 23, 2026
Owned after transaction
63.8K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
2
What this establishes
Bizily Scott filed this Form 4 reporting a option exercise of FDMT on Jun 23, 2026. It became public on Jun 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Legal Officer
Bizily Scottcik:0001920738
Issuer
4D Molecular Therapeutics, Inc.cik:0001650648
Revision history · 0
No field has changed since this record was first ingested.
FDMT4D Molecular Therapeutics, Inc.